StockNews.com downgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a hold rating to a sell rating in a research report released on Saturday. Other research analysts have also recently issued reports about the company. Oppenheimer boosted their price target on Corbus Pharmaceuticals from $58.00 to $60.00 and gave the stock an outperform rating […]
Corbus Pharmaceuticals (NASDAQ:CRBP) Given New $60.00 Price Target at Oppenheimer dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning. Separately, Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $20.00 to $51.00 and gave the company an outperform rating in a research note on […]
StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a sell rating to a hold rating in a research note published on Saturday. Separately, Oppenheimer raised their price target on Corbus Pharmaceuticals from $20.00 to $51.00 and gave the stock an outperform rating in a research report on Monday, January 29th. Get Our […]
Investment analysts at StockNews.com assumed coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) in a research note issued on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Stock Performance NASDAQ:CRBP opened at $5.50 on Friday. The stock has a fifty day moving average price of $5.20 […]